Author  
Place of duty  
Title   중등도 및 고도 비호지킨 림프종에 대한 BACOD / EISHAP 교대복합화학요법 ( BACOD / EISHAP Alternating Combination Chemotherapy for Intermediate and High Grade Non - Hodgkin`s Lymphoma )
Publicationinfo   2000 Jan; 032(04): 793-801.
Key_word   Non-Hodgkin;s lymphoma, BACOD/EISHAP altimating combination chemotherapy
Full-Text  
Abstract   Purpose: We conducted a phase II study to determine the antitumor activity of BACOD/EISHAP alternating 9-drug chemotherapy in previously untreated patients with intermediate or high grade non-Hodgkin's lymphoma (NHL). Materials and Methods: Intermediate or high grade non-Hodgkin's lymphoma patients were treated with BACOD/EISHAP (bleomycin, doxorubicin, cyclophosphamide, vincristine, dexamethasone/etoposide, ifosfamide, high dose cytarabine, cisplatin, dexamethasone) alternating com-bination chemotherapy. Stage I and IIA lymphoma patients were excluded. BACOD/EISHAP alternating chemotherapy was given to the eligible patients every 3 weeks/4 weeks respectively. Results: Between April, 1995 and December, 1997, among 25 eligible patients, 19 patients were evaluable for response. Six patients could not be evaluated for response because of follow-up loss within 2 cycles of chemotherapy. Complete response (CR) was achieved in 12 patients (63%) after BACOD/EISHAP alternating combination chemotherapy. With a follow-up period of 41 months (25-57 months), the disease free survival did not reach median (4-47 months) and 3-year disease free survival rate was 75%. Major toxicity was marrow suppression and the incidence of severe leukopenia (WBC < 2,000/mm) and thromobocytopenia ( <. 25,000/mm') were 15%, 5%, respectively. No treatment-related death was observed. For non-hematologic toxicities, nausea and vomiting were observed in 65% of patients, stomatitis in 25%, peripheral neuropathy in 20%. Conclusion: BACOD/EISHAP alternating chemotherapy was feasible with acceptable toxicities. The 63% complete response rate was comparable to other regimcns but 75% 3year disease-free survival rate was encouraging. Further evaluation of this regimen is warranted. Key Words: Non-Hodgkin's lymphoma, BACOD/EISHAP alternating combination chemotherapy
저 자   장정순(Joung Soon Jang),강정훈(Joung Hun Kang),박영호(Young Ho park),김수진(Soo Jin Kim),윤지철(Ji Chul Yun),이경원(Gyeong Won Lee),김훈구(Gun Gu Kim),황인규(In Gyu Hwang),이원섭(Won Sup Lee),이종석(Jong Seok Lee)